The biopharmaceutical company and medical technology firm will host a virtual event to discuss the future of diabetes treatment and innovation in the sector.
The biopharmaceutical company and medical technology firm will host a virtual panel discussion on the treatment journey for people with diabetes and factors driving future innovation.
The biotechnology company has announced a change in director shareholding.
The biotechnology company has announced a change in director shareholding.
The biopharmaceutical company has secured additional patent protection for its key development programmes, enhancing the intellectual property around its innovative therapies.
The biopharmaceutical company announces changes to its board, including a new Non-Executive Director and Chair of the Audit & Risk Committee, as well as the promotion of the CFO to an Executive Director role.
The clinical-stage biopharmaceutical firm reported progress in its diabetes and obesity portfolios, secured a co-development deal, and extended its cash runway through a royalty financing agreement.
The biopharmaceutical company has signed a co-development agreement with an insulin delivery technology firm and raised non-dilutive capital through the monetization of royalty rights.
The biopharmaceutical company will announce its interim results for the six months ended 30 June on Thursday 25 September 2025.
The biopharmaceutical company has received positive feedback from the FDA on the Phase 2 clinical study design for its ultra-concentrated and ultra-rapid acting insulin, AT278, to be used in combination with an Automated Insulin Delivery system.